Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 22
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Title
Phase
Protocol IDs
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Phase III, Phase II
06-2247
NCT00442533
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Phase III
A6181111
NCT00428597
Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors
Phase III
CRAD001C2324
NCT00510068
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Phase II, Phase I
UCSF-04458
NCT00227617
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
Phase II, Phase I
CTCT 06-11
NCT00493883
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase II, Phase I
07-325
NCT00576680
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Phase II
NCI-04-C-0273
NCI-6332, DELCATH-G990039, NCT00096083
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Phase II
END0002
97273, END0002, NCT00398320, NCT00398320
Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer
Phase II
MDA-2006-0077
MDACC 2006-0077, 7650, NCT00454363
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Phase II
MCC-14888
NCT00434109
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute